<DOC>
	<DOCNO>NCT00000768</DOCNO>
	<brief_summary>To determine oral bioavailability three dose level oral ganciclovir give without glutamic acid hydrochloride patient cytomegalovirus ( CMV ) GI disease , compare bioavailability regimens standard intravenous ( IV ) ganciclovir . Long-term ganciclovir maintenance therapy recommend CMV colitis esophagitis follow induction treatment . Oral ganciclovir likely candidate maintenance possible therapeutic value ease administration , optimum dose determine . Since oral ganciclovir low bioavailability soluble acid pH environment , addition glutamic acid hydrochloride may enhance gastrointestinal absorption drug .</brief_summary>
	<brief_title>A Randomized Comparative Pharmacokinetic Study Oral Ganciclovir After Treatment With Intravenous Ganciclovir Cytomegalovirus Gastrointestinal Disease AIDS Patients</brief_title>
	<detailed_description>Long-term ganciclovir maintenance therapy recommend CMV colitis esophagitis follow induction treatment . Oral ganciclovir likely candidate maintenance possible therapeutic value ease administration , optimum dose determine . Since oral ganciclovir low bioavailability soluble acid pH environment , addition glutamic acid hydrochloride may enhance gastrointestinal absorption drug . All patient receive induction regimen IV ganciclovir administer twice daily 21 42 ( Per Amendment 3/4/95 ) day . A permanent venous catheter implant induction therapy . If clinically improve following induction , patient randomize receive one three dose oral ganciclovir , give first without oral glutamic acid hydrochloride , every 8 hour reach steady state . PER AMENDMENT 3/14/95 : After subject reach steady state oral ganciclovir glutamic acid hydrochloride PK sample take . Subjects continue dose regimen assign ( glutamic acid hydrochloride add result least 33 % increased bioavailability ) 12 month relapse CMV GI disease document . Subjects follow monthly interval safety evaluation evidence CMV GI relapse . Subjects clinical symptom relapse undergo repeat endoscopy colonoscopy document relapse .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Recommended : PCP prophylaxis . Allowed : Antiretroviral therapy induction pharmacokinetic part study , provide patient remain antiretroviral therapy duration study . Chemotherapy Kaposi 's sarcoma , provide patient hematologically stable least 30 day prior study entry . Recombinant human erythropoietin . GMCSF GCSF . Other medication necessary patient 's welfare , physician 's discretion . Patients must : HIV infection . Biopsyproven cytomegalovirus ( CMV ) colitis . Life expectancy least 3 month . No active AIDSdefining opportunistic infection require therapy know cause nephrotoxicity myelosuppression . NOTE : Kaposi 's sarcoma permit patient hematologically stable least 30 day prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Other etiology diarrhea identify study entry . PER AMENDMENT 3/14/95 : For subject diarrhea etiology diarrhea identify within 6 week enrollment . Known hypersensitivity study drug . CMV retinitis . Concurrent Medication : Excluded : Acyclovir probenecid ( PER AMENDMENT 3/14/95 ) . Immunomodulators . Biologic response modifier ( GMCSF GCSF ) . Investigational agent , exception treatment IND drug . Antacids . H2 blocker . Proton pump inhibitor . Foscarnet induction pharmacokinetic part study . Intravenous CMV retinitis maintenance therapy ( include ganciclovir ) pharmacokinetic part study . Nephrotoxic agent . Prior Medication : Excluded within 14 day prior study entry : Immunomodulators . Biologic response modifier ( GMCSF GCSF ) . Investigational agent , exception treatment IND drug .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Intestinal Absorption</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Colitis</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Biological Availability</keyword>
	<keyword>Glutamic Acid</keyword>
</DOC>